TMO - Thermo Fisher Scientific Inc.
A wild Thursday saw Treasury yields crater, oil surge past $111, crypto liquidations top $431 million, and Meta's cash flow surprise rattle markets. Now analysts are reshuffling their calls on some of the week's most closely watched names.
Thermo Fisher Scientific Inc. delivered strong Q3 results, with 6% organic growth, EPS and sales beats, and raised full-year guidance. TMO's growth is driven by robust demand in clinical research, bioproduction, and electron microscopy, supported by recent strategic acquisitions. Operating margin reached 24.5%, aided by divestitures, acquisitions, and ongoing process improvements.
Thermo Fisher raised its 2026 organic revenue growth outlook to 4%. Third-quarter revenue reached $12.14 billion with 6% organic growth.
Life-sciences tools giant Thermo Fisher Scientific (TMO) reported a strong third quarter Wednesday, with revenue up 9% and adjusted earnings per share up 15%. S
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 1% on Wednesday.
Thermo Fisher Scientific Inc. (TMO) Q3 2026 Earnings Call Transcript
Thermo Fisher beats Q3 earnings and revenue estimates, with double-digit profit growth and wider margins, yet shares fall 4.1% in pre-market trading.
Although the revenue and EPS for Thermo Fisher (TMO) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Thermo Fisher Scientific Inc. delivered 6% organic growth, 120 bps margin expansion, and 39% free cash flow growth in Q3, validating the ongoing recovery. I maintain a Strong Buy rating on TMO, supported by accelerating earnings, improved profitability, and a declining net debt/EBITDA ratio (now 2.9x). Laboratory Products and Biopharma Services led with 10% organic growth, while Analytical Instruments posted 430 bps margin expansion, though Life Sciences and Diagnostics remain slower.
Thermo Fisher Scientific NYSE: TMO reported third-quarter revenue growth of 9% to $12.14 billion, supported by 6% organic growth, acquisitions and foreign-exchange effects. Adjusted earnings per share rose 15% to $6.68, while adjusted operating income increased 15% to $2.97 billion.
Thermo Fisher Scientific Inc (NYSE:TMO, XETRA:TN8) increased third-quarter revenue by 9% to $12.14 billion, while adjusted earnings per share rose 15% to $6.68. Revenue for the three months ended September 2026 increased from $11.12 billion a year earlier, with organic revenue growth, which excludes the effects of acquisitions, disposals and currency movements, reaching 6%.
Thermo Fisher Scientific (TMO) came out with quarterly earnings of $6.68 per share, beating the Zacks Consensus Estimate of $6.4 per share. This compares to earnings of $5.79 per share a year ago.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 26, 2026. Third Quarter Highlights Third quarter revenue grew 9% to $12.14 billion Third quarter GAAP diluted earnings per share (EPS) grew 9% to $4.64 Third quarter adjusted EPS grew 15% to $6.68 “We are very pleased to deliver another excellent quarter, with outstanding financial performance on both the top.
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Thermo Fisher Scientific Inc. (NYSE:TMO) will release its third quarter earnings report before the opening bell on Wednesday, Oct. 21.
Investors looking beyond artificial intelligence (AI) should closely watch two healthcare names – Thermo Fisher Scientific (TMO) and Waters (WAT) – according to Josh Brown. In his latest report, the Ritholtz' chief executive highlighted laboratory equipment suppliers whose improving businesses are attracting buyers as tech stocks face pressure.
On October 19, 2026, we conducted a DCF analysis for Thermo Fisher Scientific Inc (TMO), a company that has shown impressive price performance over the past yea
Banque Pictet and Cie SA cut its stake in Thermo Fisher Scientific Inc. (NYSE: TMO) by 26.1% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,703 shares of the medical research company's stock after selling 6,618 shares during the
Besides Wall Street's top-and-bottom-line estimates for Thermo Fisher (TMO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.
On CNBC's “Halftime Report Final Trades,” Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, picked U.S. 10 Year Treasury.